Estrogen receptor β agonist inhibits proliferation of endometrial stromal cells in an estrogen-receptor independent manner by Xia Qiong et al.
Arch. Biol. Sci., Belgrade, 66 (2), 735-741, 2014 DOI:10.2298/ABS1402735X
735
ESTROGEN RECEPTOR Β AGONIST INHIBITS PROLIFERATION OF ENDOMETRIAL 
STROMAL CELLS IN AN ESTROGEN-RECEPTOR INDEPENDENT MANNER
QIONG XIA1, DONG ZHAO2 and JUAN WANG1
1 Department of Obstetrics, Gynecology, Wuhan Puai Hospital, Wuhan, China  
2 Department of Obstetrics, Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of 
Medicine, Shanghai, China
Abstract - The finding that estrogen receptor ERβ agonists induce regression of ectopic endometrial implants in a rodent 
model has rekindled interest in the role of ERβ in the growth and maintenance of human endometriosis. We hypothesize 
that the ERβ agonist may have a direct effect on the human endometrium. We examined the mRNA and protein expression 
of ERβ in both eutopic and ectopic endometrium and performed a luciferase reporter assay for the presence of functional 
ERβ in human endometrial stromal cells. Diarylpropionitrile (DPN – a ERβ specific agonist) significantly inhibited en-
dometrial stromal cell proliferation at 10 M by 25% but not at 10 nM. ERβ mRNA is present in both eutopic and ectopic 
endometrium; however, protein expression is absent in both stroma and epithelium. Our search for functional ERβ simi-
larly showed an absence in endometrial stromal cells. These results suggest that the regression of endometriosis might be 
ERβ-independent. 
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INTRODUCTION
Endometriosis is a complex gynecological disorder 
associated with pelvic pain and infertility. It affects 
between 5-15% of reproductive-age women (Gold-
man and Cramer 1990). The most important patho-
genetic changes of endometriosis is its dependence 
on estrogen for growth, and the absence of a con-
sistent response to progesterone or synthetic pro-
gestins (Bulun, Cheng et al. 2006). Current research 
has focused on specific aspects of the pathogenetic 
pathway of endometriosis. These include progester-
one receptor (PR) modulators, tumor necrosis factor 
(TNF-α) inhibitors (Vigano 2003), angiogenesis in-
hibitors (Nap, Griffioen et al. 2004), matrix metallo-
proteinase inhibitors (D’Hooghe 2003), pentoxifyl-
line (Szamatowicz, Laudanski et al. 2000), and most 
recently, estrogen receptor (ER) beta agonists (Har-
ris, Albert et al. 2003). 
In 1995, a second ER was cloned (Kuiper, En-
mark et al. 1996); the former ER is now referred 
to as ERα and the latter as ERβ. Because endome-
triosis is an estrogen-dependent disease, the role of 
this estrogen receptor in endometriosis has been 
studied by several researchers. Controversy exists 
regarding the expression of specific ER proteins in 
the human endometrium. Analyses of the two ER 
isoforms indicate that eutopic normal endometrial 
stromal cells and endometrioma stromal cells both 
predominantly express ERα mRNA (Brandenberg-
er, Lebovic et al. 1999). However, several researchers 
found markedly higher levels of ERβ and lower lev-
els of ERα in human endometriotic tissues and pri-736 QIONG XIA ET AL.
mary stromal cells compared with eutopic endome-
trial tissues and cells (Brandenberger, Lebovic et al. 
1999; Fujimoto, Hirose et al. 1999). The increased 
expression of ERβ in endometriosis may also in turn 
affect the levels of expression of ERα and PR (Bulun, 
Cheng et al. 2010). The models of action involving 
cooperation,  as  well  as  competition,  between  the 
two ER proteins have been proposed (Matthews and 
Gustafsson 2003). These findings suggest that addi-
tional research is needed to explore the role of ER in 
endometriosis.
Recently, the effects of an ERβ ligand were ex-
amined (Harris 2007). The effectiveness of a specific 
ERβ agonist in treating endometriosis in the rodent 
model has suggested that this compound may be a 
promising new treatment in combating the disease 
(Harris, Bruner-Tran et al. 2005). The current study 
tested the hypothesis that an ERβ agonist might have 
an inhibitory effect on endometriosis by acting di-
rectly on the ectopic endometrium.
MATERIALS AND METHODS
Patient recruitment, tissue acquisition and charac-
terization
Healthy  women  with  ovulatory  menstrual  cycles, 
who had not received hormones or GnRH agonist 
therapy for at least 6 months before surgery, were en-
rolled in this study. Subjects undergoing elective sur-
gery for leiomyomata uteri or other benign uterine 
conditions  were  recruited  for  normal  endometrial 
biopsies. Biopsies were obtained after the patients 
provided written informed consent, under a study 
protocol approved by the Committee on Human Re-
search at the University of Wisconsin, Madison.
Human endometrial stromal cell cultures
Stromal  cells  were  separated  from  glandular  cells 
and debris by filtration through narrow-gauge sieves. 
Stromal cells were plated and subcultured to eliminate 
contamination by macrophages or other leukocytes. 
Extensive characterization of cell cultures confirmed 
that they were >95% pure and retained functional 
markers of their endometrial origin (Ryan, Schriock 
et al. 1994).
RT-PCR
Total  RNA  was  extracted  from  endometrium  and 
endometriosis lesions using the TRIzol reagent kit 
(GIBCO  BRL,  Gaithersburg,  MD).  After  reverse 
transcription of 5 µg of total RNA using oligo (dT) 
primers  and  a  Moloney  Murine  Leukemia  Virus 
Transcriptase kit (Promega, USA), the resulting sin-
gle-stranded cDNA was subjected to PCR. The prim-
ers were designed using GeneFisher software. The 
forward and reverse primers used were: ERβ forward, 
5’- TTC CTC CTA TGT AGA CAG CCA CCA T -3’; 
ERΒ ERβ reverse, 5’- TAC CAA CTC CTT GTC GGC 
CAA  CT  -3’.  cyclophilin  forward,  5’  –CCG  AGG 
AAA ACC GGG TAC TAT –3’, cyclophilin reverse, 
5’ –AGA TTC TAG GAT ACT GCG AGC A–3’. The 
expected final PCR products from human ERβ were 
800 bases long; the PCR products from human cyclo-
philin were 600 bases long. The PCR programs used 
were: 35 cycles of 1 min at 94°C, 1 min at 59°C, 2 min 
at 72°C. Final products were extended to full length 
by incubation for 5 min at 72°C. Reaction products 
were separated on 1% agarose gels.
Treatment of stromal cells with ER agonists
Steroid hormones were added in 0.1% ethanol di-
rectly to the cells growing in MEM-α media with 5% 
charcoal stripped serum. The concentrations of lig-
ands are listed as follows: 17β Estradiol 10-8 M, 10-9 M 
(Sigma, St. Louis, MO), DPN 10-8 M, 10-5 M (Tocris 
Cookson, Ellisville, MO).
Gene promoters and luciferase assays
The synthetic strogen response element (ERE) con-
struct and ERβ expression vector were gifts from Dr. 
Jyoti  Watters  (University  of  Wisconsin-Madison). 
The ERβ expression vector was a gift from Dr. Elaine 
Alarid (University of Wisconsin-Madison). All con-
structs were sequenced by the University of Wiscon-
sin Madison Biotechnology Center to verify that the 
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Transient transfections were performed in hu-
man  endometrial  stromal  cells  grown  in  MEM-α 
with  5%  charcoal  stripped  serum  and  antibiotics 
in 12-well plates at ~50% confluence. 1 µg of ERE 
promoter (firefly luciferase, experimental reporter) 
was  added  to  each  well  using  QIAGEN  Polyfect® 
reagent (Valencia, CA, USA). The ERE transfection 
efficiencies were normalized to an independent con-
trol plasmid (0.5µg ß-galactosidase expression vec-
tor) that was co-transfected simultaneously. In some 
experiments, ERα and ERβ were over-expressed by 
co-transfection of an expression vector (0.5µg/well). 
A non-specific vector was added to normalize total 
transfected DNA in each well. The results are pre-
sented as luciferase activity after correcting for trans-
fection efficiency. The reporter vector was assayed in 
at least three independent cultures. The same amount 
of empty vector was analyzed in pilot experiments as 
a control and revealed low basal activity. 
Immunohistochemistry
Paraffin sections (5 µm) were mounted, deparaffi-
nized in  xylene,  and  hydrated  gradually  through 
decreasing  concentrations of  ethanol  followed  by 
a wash in tap water. The slides were then placed in 
citrate buffer (pH 6.0), microwaved to the point of 
boiling and then left in hot buffer for an additional 
30 min for antigen retrieval. Endogenous peroxidase 
was quenched with methanolic hydrogen peroxide 
(3%) for 10 min, followed by running tap water rinse 
to clear. The slides were rinsed three times in PBS 
(pH 7.4) and incubated with horse serum (Sigma, 
St. Louis, MO). Subsequently, they were incubated 
with  mouse  anti-human  ERβ  antibodies  (Serotec 
MCA1974T, Oxford, UK) in PBS at 25oC for 1 h, fol-
lowed by three rinses with PBS. The slides were then 
incubated  with  biotinylated horse  anti-mouse  an-
tibodies (Vector Lab, Burlingame, CA) for 30 min, 
followed by three rinses with PBS. Chromogen was 
developed  using  Novared  hydrogen  peroxide  sub-
strate (Vector Lab, Burlingame, CA) for 5-8 min and 
after washing in tap water counterstained in Harris 
hematoxylin  for  5  min.  Negative control  sections 
were incubated with control isotype IgG. Photogra-
phy was performed using a microscope (Leica, Wet-
zlar, Germany) with Magnafire photomicrographic 
equipment (Optronics, Goleta, CA).
Proliferation assay
The BrdU labeling and detection kit measures cell 
proliferation by quantitating BrdU incorporated into 
the newly synthesized DNA of replicating cells. The 
incorporated BrdU can be detected by a quantitative 
cellular enzyme immunoassay (Biotrak, Amersham 
Pharmacia Biotech Ltd, UK) using mAbs directed 
against BrdU. Briefly, the endometrial stromal cells 
were cultured in 96-well microtiter plates (104 cell/
well). Cells are allowed to attach for 3 h and then 
cultured  with  5%  charcoal  striped  serum  media 
overnight. After a 12 h pre-incubation period with-
out serum, the respective cells were treated with E2 
10-9 M DPN 10-8 and 10-5 M in a serum-free medium 
and incubated for an additional 24 h. After that, the 
cells were labeled with 10 µmol/l BrdU (100 µl/well) 
and incubated for 4 h at 37°C. The cells were fixed 
and genomic DNA was denatured by adding 200 µl/
well of blocking reagent (1:10) for 30 min at room 
temperature. Peroxidase-labeled anti-BrdU antibody 
(1:100) was added (100 µl/well) and incubated for 90 
min at room temperature. After washing three times, 
TMB (3,3’5,5’-tetramethylbenzidine) substrate solu-
tion was added (100 µl/well) and incubated for 15 
min at room temperature for color appearance, and 
finally optical density was measured using a micro-
plate reader at an absorbance of 450 nm. The absorb-
ance values correlated directly to the amount of DNA 
synthesis and thereby to the number of proliferating 
cells in culture.
Data presentation and statistical analysis
ERE luciferase assay data are expressed as mean± 
standard deviation (SD) for at least three independ-
ent  experiments.  The  number  of  experiments  is 
represented as “n” in the Results section below. As 
normalized data were expressed as a percentage of 
controls, the results were compared with non-para-
metric Mann-Whitney or Kruskal-Wallis tests using 
Minitab software. Two tailed tests with P<0.05 were 
considered significant.738 QIONG XIA ET AL.
RESULTS
ERβ mRNA expression in human endometrium:
The results of RT-PCR analyses of ERβ expression in 
the endometrium of women with endometriosis or 
without endometriosis are summarized in Table 1 (E 
stands for endometrium, O stands for endometrio-
sis lesion). ERβ mRNA is expressed in 7 out of the 8 
endometrial samples. The two endometriosis lesions 
also express ERβ mRNA. Fig. 1 is a photograph of a 
representative gel.
Immunohistochemistry
For detection of ERβ protein expression in human 
endometrium and endometriosis lesions, immuno-
histochemistry  was  performed.  Human  ovary  was 
used  as  a  positive  control  (Saunders,  Millar  et  al. 
2000) and isotype-matched mouse IgG was used as a 
negative control in all staining experiments. Fig. 2A 
shows the ovary stained with ERβ antibody; positive 
granulosar cells are indicated with an arrow. Nuclear 
staining is found in granulosar cells and theca cells. 
Fig. 2B shows the results of normal cycling human 
endometrium; the positive endothelial cells are indi-
cated with an arrow. Fig. 2C shows an endometriosis 
lesion with ERβ staining. As can been seen, neither 
endometrial  stromal  cells  nor  epithelial  cells  are 
positive for ERβ; positive staining is found in some 
endothelial cells. 
ERE reporter assay: (N=4)
Since  the  immunohistochemical  study  showed  no 
expression of ERβ protein in normal or pathological 
endometriosis, we designed an additional study to 
determine whether there is functional ERβ in human 
endometrium. Primary cultures of human endome-
trial  stromal  cells  were  transfected  with  plasmid 
containing  the  luciferase  reporter  gene  under  the 
control of ERE. After transfection, cells were treated 
with 17β estradiol or a specific ERβ agonist (DPN), 
with or without co-transfection of ERβ or ERβ genes. 
β-galactosidase plasmid served as a transfection con-
trol. An ERE construct without any treatment served 
as negative control; co-transfection of ERα and ERβ 
expression vectors served as positive control. DPN 
plus ERE luciferase were to test whether there is any 
functional ERβ in endometrial stromal cells. The re-
sults are summarized in Table 2, and show that there 
is no functional ERβ in endometrial stromal cells.
BrdU incorporation assay: (n=5)
Treatment of endometrial stromal cells with 17β es-
tradiol at 1 nM significantly increased BrdU incor-
poration  by  33±56%,  DPN  at  10  µM  significantly 
inhibited BrdU incorporation by 24±25%, while at 
the concentration of 1 nM and10 nM, BrdU incorpo-
ration was 102±6% and 121±32%, respectively, and 
there was no significant difference compared with 
vehicle control (Fig. 3). 
DISCUSSION
Endometriosis  is  a  debilitating  disease  that  is  not 
adequately  treated  by  currently  available  medical 
therapies. The effectiveness of a specific ERβ ago-
Fig. 1. Representative gel of PCR product
PCR products from human endometrium RNA were separated 
on a 1% agarose gel; lane 1 is E0480 amplified with ERβ primer; 
lane 2 is E2754 amplified with ERβ primer; lane 3 is a DNA lad-
der; lane 4 is E0480 amplified with cyclophilin primer; lane 5 is 
E2754 amplified with cyclophilin primer. ERβ AGONIST SUPPRESSES PROLIFERATION 739
Fig. 2. Immunohistological staining of human endometrium with ERβ antibody. (A) Normal cycling human ovary served as positive 
control; the arrow indicates positive granulosar cells and theca cells. (B) Normal human endometrium stained with monoclonal ERβ 
antibody; positive endothelial cells are indicated with an arrow. (C) An ovarian endometriosis lesion stained with ERβ antibody. (D) 
Negative control stained with isotype control IgG. 
Fig. 3. Effects of 17β estradiol or the ERβ agonist DPN on the cell proliferation ability of human endometrial stromal cells. Human endo-
metrial stromal cells were treated with 1 nM 17β Estradiol or DPN (10 µM, 1 nM and10 nM, separately) for 24 h and the content of BrdU 
incorporation was detected with the BrdU labeling and detection kit. The shaded bars and error bars represent the means and standard 
deviations, respectively, determined from at least three independent assessments of 100 cells each in a single experiment; similar results 
were obtained in three independent experiments. Control-untreated group, 1-1 nM 17β estradiol-treated group, 2-10 µM DPN-treated 
group, 3-1 nM DPN-treated group, 4-10 nM DPN-treated group; ﹟ indicated P<0.05 compared with control groups.740 QIONG XIA ET AL.
nist in treating endometriosis in the rodent model 
has suggested that this compound may be a promis-
ing new treatment in combating the disease (Harris, 
Bruner-Tran et al. 2005). The ERβ agonist is effec-
tive not only in intact mice, but also in nude mice 
and ovariectomized mice, which suggests that the 
possible  mechanism  that  caused  the  regression  of 
endometriosis  is  not  mediated  by  the  immune  or 
endocrine systems. The current study tested the hy-
pothesis that an ERβ agonist might have an inhibi-
tory effect on endometriosis by acting directly on the 
ectopic endometrium.
In this study, the mRNA expression of ERβ in 
human endometrium is in agreement with previous 
investigations (Brandenberger et al., 1999; Critchley 
et al., 2002). However, immunohistochemistry failed 
to demonstrate that ERβ protein was expressed in 
ectopic endometrium, aside from its presence in en-
dothelial cells. This absence of ERβ is in agreement 
with the findings of some authors (Fazleabas et al., 
2003), but in conflict with others (Critchley et al., 
2002). Recently, Xue et al. found that the ERβ mRNA 
was  strikingly  higher  (~34-fold)  in  endometriotic 
stromal cells, whereas it was much lower or nearly 
absent in endometrial stromal cells (Xue et al., 2007). 
The presence of ERβ in endometrial endothelium is 
in agreement with Critchley et al. (2001). The dis-
crepancies of ERβ expression may be relevant for tis-
sues from different sources, the detection methods 
and the detection levels.
In an attempt to determine which of these expla-
nations is correct, we used an ERE reporter construct 
to test for functional ERβ in endometrial stromal 
cells. This approach was expected to be more sen-
sitive than immunohistochemistry for detection of 
ERβ  protein  expression.  Although  the  experiment 
showed  endogenous  ERβ  expression,  as  well  as  a 
strong and consistent response of the ERE construct 
to co-transfection of ERα and ERβ, no endogenous 
ERβ activation of the ERE was identified in response 
to the ERβ specific ligand. Our results indicate that 
the ERβ protein is not present in human endome-
trial stromal cells and epithelial cells, although the 
mRNA is transcribed. Eukaryotic cells possess a va-
riety of means by which they are able to regulate the 
expression of the genes they contain. These mecha-
nisms include control at the level of transcription, 
differential splicing, regulation of the nuclear export 
of  transcripts,  modulation  of  mRNA  stability  and 
changes in the rates of translation of specific mRNAs. 
Although transcriptional regulation is obviously cru-
cial, the control of gene expression also relies heav-
ily on translational selectivity and the mechanism 
of protein synthesis provides the cell with a variety 
of sophisticated and subtle means to modulate the 
rates of production of key proteins, independently of 
events in the nucleus. We hypothesize that either the 
ERβ protein is not translated or the expression of the 
ERβ protein is not detectable by immunostaining.
Recently, some researchers suggested that ERβ 
agonists might be useful as a novel therapeutic ap-
proach to improve ovarian function in sub- or in-
fertile women (Hegele-Hartung, Siebel et al. 2004; 
Zhao, Dahlman-Wright et al. 2008). Another study 
showed  that  an  ERβ-selective  agonist  is  effective 
against inflammatory pain and this may contribute 
to the endometriosis-related pelvic pain (Leventhal, 
Brandt et al. 2006). In our study, the ERβ agonist 
DPN inhibited BrdU incorporation at 10 µM but not 
at 10 nM, while the EC50 values for E ERβ was 66 
nM, and there was no detectable ERβ protein in the 
endometrial stromal cells. These results indicate that 
the significant inhibition of proliferation with 10 µM 
DPN might not mediated by ERβ. 
Previously we reported that endometrial stromal 
cells  express  an  aryl  hydrocarbon  receptor  (AhR) 
(Zhao, Pritts et al. 2002). AhR is known to cause G1 
arrest and proliferation inhibition in other cell types 
(Laiosa, Wyman et al. 2003; Jin, Jung et al. 2004). 
Further studies need to be performed in order to in-
vestigate whether the proliferation inhibition and re-
gression of endometriosis caused by an ERβ agonist 
is also mediated by AhR. 
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